The gut microbiome across the cardiovascular risk spectrum.

Autor:	Prins FM; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands., Collij V; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands., Groot HE; University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands., Björk JR; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands., Swarte JC; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands., Andreu-Sánchez S; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Pediatrics, Groningen, The Netherlands., Jansen BH; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands., Fu J; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Pediatrics, Groningen, The Netherlands., Harmsen HJM; University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection prevention, Groningen, The Netherlands., Zhernakova A; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands., Lipsic E; University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands., van der Harst P; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands., Weersma RK; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands., Gacesa R; University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands.; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands.
Jazyk:	angličtina
Zdroj:	European journal of preventive cardiology [Eur J Prev Cardiol] 2024 Jun 03; Vol. 31 (8), pp. 935-944.
DOI:	10.1093/eurjpc/zwad377
Abstrakt:	Aims: Despite treatment advancements, cardiovascular disease remains a leading cause of death worldwide. Identifying new targets is crucial for enhancing preventive and therapeutic strategies. The gut microbiome has been associated with coronary artery disease (CAD), however our understanding of specific changes during CAD development remains limited. We aimed to investigate microbiome changes in participants without clinically manifest CAD with different cardiovascular risk levels and in patients with ST-elevation myocardial infarction (STEMI). Methods and Results: In this cross-sectional study, we characterized the gut microbiome using metagenomics of 411 faecal samples from individuals with low (n = 130), intermediate (n = 130), and high (n = 125) cardiovascular risk based on the Framingham score, and STEMI patients (n = 26). We analysed diversity, and differential abundance of species and functional pathways while accounting for confounders including medication and technical covariates. Collinsella stercoris, Flavonifractor plautii, and Ruthenibacterium lactatiformans showed increased abundances with cardiovascular risk, while Streptococcus thermophilus was negatively associated. Differential abundance analysis revealed eight species and 49 predicted metabolic pathways that were differently abundant among the groups. In the gut microbiome of STEMI patients, there was a depletion of pathways linked to vitamin, lipid, and amino acid biosynthesis. Conclusion: We identified four microbial species showing a gradual trend in abundance from low-risk individuals to those with STEMI, and observed differential abundant species and pathways in STEMI patients compared to those without clinically manifest CAD. Further investigation is warranted to gain deeper understanding of their precise role in CAD progression and potential implications, with the ultimate goal of identifying novel therapeutic targets. Competing Interests: Conflict of interest: R.K.W. acted as consultant for Takeda, received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico, and Ferring, and received speaker fees from MSD, Abbvie, and Janssen Pharmaceuticals. E.L. received an educational grant from Abbott. All other authors declare that they have no relevant competing financial interests or relationships that could have influenced the work reported in this article. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu